Equity Profile

SLNO

Soleno Therapeutics, Inc.

Health CareBiotechnology

Mar23Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare diseases. Operating in the health care sector, it aims to address unmet medical needs through its specialized drug development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In Q1-2026, Soleno reported an EPS of $0.59, which was below the expected $0.73, resulting in a 19.4% negative surprise. The stock experienced a slight increase of 0.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Soleno's upcoming earnings report are mixed, given the company's recent performance and lack of analyst estimates.

Bull Case

If Soleno can exceed EPS expectations and demonstrate strong revenue growth, it could signal a positive turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Soleno provide a clear outlook on revenue growth for its key therapies?

A solid revenue forecast could reassure investors about the company's growth potential, especially after recent earnings misses.

How does management plan to address the recent EPS misses?

Understanding management's strategy to improve profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Soleno's potential for a turnaround given its recent innovations in rare disease therapies, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent EPS surprises indicate potential for significant upside if they can capitalize on their product pipeline.

Options pricing suggests a higher volatility expectation, indicating that investors may be anticipating a significant move in either direction.

Key Risk

If Soleno's revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a series of mixed results, and investors are looking for signs of recovery.

Bull Confirmed If

A positive EPS surprise of at least 10% would confirm the bull case.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 5.47%, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 2.04% on the next trading day, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses earnings expectations again, history indicates a potential drop of around 0.20% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key therapies in development.
2Management's commentary on addressing past earnings misses.
3Insights into market demand for Soleno's products.
4Guidance on future revenue expectations.
5Any strategic partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

PDD Holdings Inc.

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In Q1-2026, Soleno reported an EPS of $0.59, which was below the expected $0.73, resulting in a 19.4% negative surprise. The stock experienced a slight increase of 0.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Soleno's upcoming earnings report are mixed, given the company's recent performance and lack of analyst estimates.

Bull Case

If Soleno can exceed EPS expectations and demonstrate strong revenue growth, it could signal a positive turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Soleno provide a clear outlook on revenue growth for its key therapies?

A solid revenue forecast could reassure investors about the company's growth potential, especially after recent earnings misses.

How does management plan to address the recent EPS misses?

Understanding management's strategy to improve profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Soleno's potential for a turnaround given its recent innovations in rare disease therapies, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent EPS surprises indicate potential for significant upside if they can capitalize on their product pipeline.

Options pricing suggests a higher volatility expectation, indicating that investors may be anticipating a significant move in either direction.

Key Risk

If Soleno's revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a series of mixed results, and investors are looking for signs of recovery.

Bull Confirmed If

A positive EPS surprise of at least 10% would confirm the bull case.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 5.47%, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise by around 2.04% on the next trading day, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses earnings expectations again, history indicates a potential drop of around 0.20% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key therapies in development.
2Management's commentary on addressing past earnings misses.
3Insights into market demand for Soleno's products.
4Guidance on future revenue expectations.
5Any strategic partnerships or collaborations that could enhance growth.